BioSante merges with Cell Genesys
LINCOLNSHIRE - BioSante Pharmaceuticals Inc. and Cell Genesys announced that they have entered into a definitive agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company. Upon completion of the transaction, BioSante stockholders before the merger are expected to own approximately 60.4 percent of the outstanding shares of the combined company and the former Cell Genesys stockholders are expected to own 39.6 percent.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.